Erythropoiesis-stimulating agents in cancer patients: Reflections on safety

Expert Review of Clinical Pharmacology

Volumn 4, Issue 4, 2011, Pages 467-476

  Wauters, Isabelle ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

cancer; chemotherapy induced anemia; erythropoiesis stimulating agents; safety; survival

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; IODINE 125; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADD ON THERAPY; ANEMIA; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON THERAPY; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; HEMATINICS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960433460     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.22     Document Type: Review

References (77)

1. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214-2221 (2001). (Pubitemid 32552805)
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl Cancer Inst. 91, 1616-1634 (1999). (Pubitemid 29479929)
3. Barrett-Lee PJ, Ludwig H, Birgegard G et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 70, 34-48 (2006).
4. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 40, 2293-2306 (2004). (Pubitemid 39348881)
5. Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur. J. Cancer 45, 1603-1615 (2009).
6. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA 82, 7580-7584 (1985). (Pubitemid 16204391)
7. Cascinu S, Fedeli A, Del Ferro E et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J. Clin. Oncol. 12, 1058-1062 (1994). (Pubitemid 24145337)
8. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86, 4446-4553 (1995).
9. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J. Clin. Oncol. 22, 2606-2617 (2004).
10. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J. Natl Cancer Inst. 94, 1211-1220 (2002). (Pubitemid 34993871)
11. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br. J. Haematol. 122, 394-403 (2003). (Pubitemid 36951623)
12. Seidenfeld J, Piper M, Flamm C et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J. Natl Cancer Inst. 93, 1204-1214 (2001). (Pubitemid 32816195)
13. Bohlius J, Langensiepen S, Schwarzer G et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl Cancer Inst. 97, 489-498 (2005). (Pubitemid 40590430)
14. Quirt I, Robeson C, Lau CY et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J. Clin. Oncol. 19, 4126-4134 (2001). (Pubitemid 33049530)
15. Varricchio CG, Sloan JA. The need for and characteristics of randomized, Phase III trials to evaluate symptom management in patients with cancer. J. Natl Cancer Inst. 94, 1184-1185 (2002). (Pubitemid 34993861)
16. Ross SD, Allen IE, Henry DH et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin. Ther. 28, 801-831 (2006). (Pubitemid 44062692)
17. Canon JL, Vansteenkiste J, Bodoky G et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J. Natl Cancer Inst. 98, 273-284 (2006). (Pubitemid 43264711)
18. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22, 1301-1307 (2004). (Pubitemid 41079845)
19. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin b increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21, 627-632 (2007). (Pubitemid 46444544)
20. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12, 231-242 (2007).
21. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin a administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 26, 1611-1618 (2008).
22. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin a. J. Clin. Oncol. 26, 1619-1625 (2008).
23. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19, 2865-2874 (2001). (Pubitemid 32538196)
24. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260 (2003). (Pubitemid 37324251)
25. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23, 5960-5972 (2005).
26. Overgaard J, Hoff CM, Hansen HS et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) -the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur. J. Cancer Suppl. 5, 6LB (2007).
27. Smith RE, Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Oncol. 26, 1040-1050 (2008).
28. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease-related anemia. J. Clin. Oncol. 25, 1027-1032 (2007). (Pubitemid 46596751)
29. Oncologic Drugs Advisory Committee, FDA. Oncologic Drugs Advisory Committee briefing document on erythropoiesis stimulating agents. US FDA, USA 2008
30. Grote T, Yeilding AL, Castillo R et al. Efficacy and safety analysis of epoetin alfa in patients with small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 23, 9377-9386 (2005).
31. Pirker R, Ramlau R, Schuette W et al. Safety and efficacy of darbepoetin a in previously untreated extensive stage small cell lung cancer treated with platinum plus etoposide. J. Clin. Oncol. 26, 2342-2349 (2008).
32. Aapro M, Leonard RC, Barnadas A et al. Effect of once-weekly epoetin b on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J. Clin. Oncol. 26, 592-598 (2008). (Pubitemid 351264353)
33. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst. 98, 708-714 (2006). (Pubitemid 43821788)
34. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373, 1532-1542 (2009).
35. Aapro M, Coiffier B, Dunst J et al. Effect of treatment with epoetin b on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br. J. Cancer 95, 1467-1473 (2006). (Pubitemid 44867480)
36. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J. Am. Med. Assoc. 299, 914-924 (2008). (Pubitemid 351397066)
37. Glaspy J, Henry D, Patel R et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur. J. Cancer 41, 1140-1149 (2005). (Pubitemid 40725572)
38. Rizzo JD, Brouwers M, Hurley P et al. American Society of Clinical Oncology -American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Clin. Oncol. 28, 4996-5010 (2010).
39. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur. J. Cancer 43, 258-270 (2007). (Pubitemid 46127840)
40. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl. 3), 33-36 (2008).
41. Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO clinical practice guidelines for use. Ann. Oncol. 21(Suppl. 5), 244-247 (2010).
42. Aapro MS, Birgegard G, Bokemeyer C et al. Erythropoietins should be used according to guidelines. Lancet Oncol. 9, 412-413 (2008). (Pubitemid 351618079)
43. Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J. Clin. Oncol. 27, 4217-4226 (2009).
44. Fandrey J, Dicato M. Examining the involvement of erythropoiesis- stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist 14(Suppl. 1), 34-42 (2009).
45. Hedenus M, Canon JL, Kotasek D et al. Effects of dose adjustment rules on safety during erythropoietic therapy: a retrospective analysis of darbepoetin alfa administered either every 3 weeks or weekly. Blood 106, (2005) (Abstract 3376).
46. Jelkmann W, Bohlius J, Hallek M et al. The erythropoietin receptor in normal and cancer tissues. Crit. Rev. Oncol. Hematol. 67, 39-61 (2008).
47. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br. J. Haematol. 141, 14-31 (2008). (Pubitemid 351347536)
48. Sinclair AM, Coxon A, McCaffery I et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115, 4264-4272 (2010).
49. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J. Clin. Oncol. 24, 4708-4713 (2006). (Pubitemid 46630934)
50. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107, 1892-1895 (2006). (Pubitemid 43289368)
51. Elliott S, Busse L, McCaffery I et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J. Immunol. Methods 352, 126-139 (2010).
52. Swift S, Ellison AR, Kassner P et al. Absence of functional EpoR expression in human tumor cell lines. Blood 115, 4254-4263 (2010).
53. Sinclair AM, Rogers N, Busse L et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br. J. Cancer 98, 1059-1067 (2008). (Pubitemid 351399799)
54. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl. 3), 21-26 (2008).
55. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225-239 (2007). (Pubitemid 47101660)
56. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 21, 327-348 (2007). (Pubitemid 47498679)
57. Koch CG, Li L, Duncan AI et al. Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann. Thorac. Surg. 81, 1650-1657 (2006). (Pubitemid 350030027)
58. Mohnle P, Snyder-Ramos SA, Miao Y et al. Postoperative red blood cell transfusion and morbid outcome in uncomplicated cardiac surgery patients. Intensive Care Med. 37(1), 97-109 (2011).
59. Hébert PC, Wells G, Blajchman MA et al.; Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N. Engl. J. Med. 340, 409-417 (1999).
60. Edna TH, Bjerkeset T. Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer. Dis. Colon Rectum 41, 451-459 (1998). (Pubitemid 28169670)
61. Dresner SM, Lamb PJ, Shenfine J et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur. J. Surg. Oncol. 26, 492-497 (2000).
62. Nosotti M, Rebulla P, Riccardi D et al. Correlation between perioperative blood transfusion and prognosis of patients subjected to surgery for stage I lung cancer. Chest 124, 102-107 (2003). (Pubitemid 36851339)
63. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst. Rev. 1, CD005033 (2006).
64. Koch CG, Li L, Sessler DI et al. Duration of red-cell storage and complications after cardiac surgery. N. Engl. J. Med. 358, 1229-1239 (2008). (Pubitemid 351439224)
65. Gafter-Gvili A, Rozen-Zvi B, Vidal L et al. Intravenous iron supplementation for the treatment of cancer-related anemia -systematic review and meta-analysis. Blood 116, (2010) (Abstract 4249).
66. Steensma DP, Sloan JA, Dakhil SR et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J. Clin. Oncol. 29, 97-105 (2010).
67. Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion 50, 719-732 (2010).
68. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol. Oncol. 116, 522-525 (2010).
69. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 102, 301-315 (2010).
70. Vekeman F, Bookhart BK, White J et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 49, 895-902 (2009).
71. Larholt K, Pashos CL, Wang Q et al. Dosing and outcomes study of erythropoiesis-stimulating therapies (DOSE): a registry for characterizing anaemia management and outcomes in oncology patients. Clin. Drug Investig. 28, 159-167 (2008). (Pubitemid 351239081)
72. Vansteenkiste J, Hedenus M, Gascon P et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level below 10 g/dl versus above or equal to 10 g/dl: exploratory analyses from a randomized, double-blind, active-controlled trial. BMC Cancer 9, 311 (2009).
73. Crawford J, Robert F, Perry MC et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J. Thorac. Oncol. 2, 210-220 (2007). (Pubitemid 47181326)
74. Charu V, Saidman B, Ben-Jacob A et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist 12, 1253-1263 (2007). (Pubitemid 350106356)
75. Schouwink JH, Codrington H, Sleeboom HP et al. Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy. Eur. J. Cancer 44, 819-829 (2008).
76. Straus DJ, Testa MA, Sarokhan BJ et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 107, 1909-1917 (2006). (Pubitemid 44582962)
77. Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer. Meta-analysis based on individual patient data. Cochrane Database Syst. Rev. 3, CD007303 (2009).